Pharmacyclics Xcytrin misses endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacyclics' Xcytrin (motexafin gadolinium) fails to show statistical significance for lung cancer patients with brain metastases in the 554-patient Phase III SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial, the firm reports Dec. 19. For the primary endpoint of time to neurologic progression (TNP), patients receiving whole brain radiation therapy plus Xcytrin had a median TNP of 15.4 months compared to 10 months for patients receiving radiation alone (p=0.122, hazard ratio=0.78). Pharmacyclics also notes there was "no significant difference in survival," a secondary endpoint. The firm plans to discuss the results with FDA; three trials looking at Xcytrin as a systemic therapy for relapsed lung cancer are ongoing...
You may also be interested in...
Pharmacyclics Xcytrin NDA in late 2006
Pharmacyclics will submit an NDA for Xcytrin (motexafin gadolinium) for treatment of patients with brain metastases with non-small cell lung cancer, the firm announces May 9. The company claims that recent analyses of its failed Phase III SMART trial show that while overall results announced in December revealed no significant improvement in progression or survival, statistical significance was achieved in the study's North American subpopulation (1Pharmaceutical Approvals Monthly January 2006, In Brief). Pharmacyclics says it has discussed the findings with FDA. SMART (Study of Neurologic Progression with Motexafin Gadolinium & Radiation Therapy) will be presented at the American Society of Clinical Oncology meeting in Atlanta on June 3...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.